These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 25646742)
21. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630 [TBL] [Abstract][Full Text] [Related]
22. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444 [TBL] [Abstract][Full Text] [Related]
23. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
24. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation. Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238 [TBL] [Abstract][Full Text] [Related]
25. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Huerta-Yepez S; Vega M; Escoto-Chavez SE; Murdock B; Sakai T; Baritaki S; Bonavida B Nitric Oxide; 2009 Feb; 20(1):39-52. PubMed ID: 18778787 [TBL] [Abstract][Full Text] [Related]
26. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5. Fassl A; Tagscherer KE; Richter J; De-Castro Arce J; Savini C; Rösl F; Roth W Cell Death Dis; 2015 Oct; 6(10):e1921. PubMed ID: 26469969 [TBL] [Abstract][Full Text] [Related]
28. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040 [TBL] [Abstract][Full Text] [Related]
29. Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx. Moon DO; Kang CH; Kang SH; Choi YH; Hyun JW; Chang WY; Kang HK; Koh YS; Maeng YH; Kim YR; Kim GY Toxicol Appl Pharmacol; 2012 Feb; 259(1):87-95. PubMed ID: 22200406 [TBL] [Abstract][Full Text] [Related]
30. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. Yang JF; Cao JG; Tian L; Liu F Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448 [TBL] [Abstract][Full Text] [Related]
31. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation. Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955 [TBL] [Abstract][Full Text] [Related]
32. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429 [TBL] [Abstract][Full Text] [Related]
33. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells. Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL. Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292 [TBL] [Abstract][Full Text] [Related]
35. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632 [TBL] [Abstract][Full Text] [Related]
36. AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules. Hwang MK; Ryu BJ; Kim SH Amino Acids; 2012 Oct; 43(4):1679-87. PubMed ID: 22354145 [TBL] [Abstract][Full Text] [Related]
37. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway. Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596 [TBL] [Abstract][Full Text] [Related]
38. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative. Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927 [TBL] [Abstract][Full Text] [Related]